Review
Nature Reviews Drug Discovery 4, 236-248 (March 2005) | doi:10.1038/nrd1660
Integrase inhibitors to treat HIV/Aids
Yves Pommier1, Allison A. Johnson1 & Christophe Marchand1 About the authors
Abstract
HIV integrase is a rational target for treating HIV infection and preventing AIDS. It took approximately 12 years to develop clinically usable inhibitors of integrase, and Phase I clinical trials of integrase inhibitors have just begun. This review focuses on the molecular basis and rationale for developing integrase inhibitors. The main classes of lead compounds are also described, as well as the concept of interfacial inhibitors of protein–nucleic-acid interactions that might apply to the clinically used strand-transfer inhibitors.
- View At a Glance
Author affiliations
- Laboratory of Molecular Pharmacology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.
Correspondence to: Yves Pommier1
Bldg 37, Room 5068, NIH, Bethesda, MD 20892-4255.
Email: pommier@nih.gov
Published online 24 February 2005
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated.
NEWS AND VIEWS
Retroviruses Closing the jointNature News and Views (03 Jun 1999)
The HIV integrase catalytic coreNature Structural Biology News and Views (01 Feb 1995)
RESEARCH
Angiotensinogen: Hormonal regulation and relative importance in the generation of angiotensin IIKidney International Original Article
Structural basis for HIV-1 DNA integration in the human genome, role of the LEDGF/P75 cofactorThe EMBO Journal Article (08 Apr 2009)
See all 7 matches for Research
